CTRI/2024/05/066786尚未招募1 期
A Randomized, Double Blind, Placebo Controlled, Multiple Cohort, Sequential Dose Escalation Phase 1 Clinical Study to Evaluate the Safety and Tolerability of HDLD-092320 in Healthy Human Volunteers - NI
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy adult male or female subjects aged between 18- 45 years.
- •2. Subjects with normal body mass index (BMI) 18.5-24.9 kg/m2
- •3. Healthy subjects as determined by the investigator based on a medical evaluation including medical history, physical examination, laboratory tests.
- •4. Subjects who refrain from taking any oral/ topical medication at least 15 days prior and during the study period. (SOS medications to be allowed during the study for any specific medical condition like paracetamol for fever).
- •5. Subjects who have not participated in any other similar clinical study within the last 3 months of screening.
- •6. Women of child-bearing potential using reliable method of contraception within 2 months of screening and willing to adopt the reliable and validated contraceptive methods throughout the study period to avoid pregnancy.
- •7. Subjects willing to sign informed consent and follow the study procedure.
排除标准
- •1. Subjects with known clinically significant nervous, endocrinal, cerebrovascular, cardiovascular, respiratory, renal, genitourinary, congenital or any other systemic disorder that can interfere with the study conduct and outcome in the opinion of the Investigator (Subject with any chronic medical condition under control to be also excluded).
- •2. Subjects with known history of GIT disorders like GERD, Gastritis, abdominal pain, diarrhea, indigestion, or any other discomfort (as assessed by GSRS score more than 1 for any one of the 15 questions to be excluded).
- •3. Subjects with known fatty liver disease grade 2 or more, history of chronic liver disease (like ALD/ NAFLD/MAFLD, chronic viral hepatitis like hepatitis B, C).
- •4. Subjects with known history of acute liver disease like acute hepatitis, within 6 months prior to the study.
- •5. Subjects with history of major surgery (like cholecystectomy) and major procedures like MRCP, ERCP.
- •6. Subjects with pre-existing systemic diseases (auto immune disorders, hormonal replacement etc.) necessitating long-term medications.
- •7. Subjects with any current infections (bacterial, fungal, viral) at the time of
- •screening as determined by the investigator.
- •8. Pregnant or lactating women (as assessed by UPT & history of amenorrhea).
- •9. Male subjects who is not willing to use adequate/ validated contraception and not willing to refrain from donating sperm from first admission to the study until 90 days after the follow-up visit.
- •10. Subjects who are not willing to refrain from alcohol or smoking from 48 hours prior and during the study.
- •11. Subjects with history of drug addiction or alcohol abuse within 5 years prior to the study
- •12. Subjects who undergo strenuous exercise within 7 days prior and during the study.
- •13. Any other reason (physical, psychological, or social) that can interfere with the subject’s compliance to the study in the opinion of the Investigator.
- •14. Subjects with known history or present condition of allergic response (like urticaria) to the study drug or any ingredients in the investigational product.
研究者
相似试验
已完成
不适用
Clinical study to evaluate effectiveness, safety and efficacy of obinil Tablet in treatment of ObesityCTRI/2019/01/016879SAVA Healthcare Ltd
已完成
不适用
A Randomized, Double Blind, Placebo Controlled, Multicentre Clinical Trial to Assess the Efficacy and Safety of Amla Extract (AMX160) in Patients with DyslipidaemiaCTRI/2015/04/005682Arjuna Natural Extracts Ltd98
尚未招募
1 期
To Investigate the Safety & Tolerability of HDCD-092330 in Healthy VolunteersCTRI/2024/04/065687Himalaya Wellness Company
已完成
2 期
Clinical study on NC009 Biscuits as an immunity enhancer in healthy individualsCTRI/2021/11/037971BRITANNIA R and D CENTRE608
已完成
2 期
Clinical study on Passiflora Extract in tension and sleep problemCTRI/2022/07/043753JK Botanicals Private Limited